Feds probing Amgen reps' allegations

It didn't take long for allegations of improper marketing from two Amgen sales reps to attract the attention of government watchdogs. First, the New Jersey Attorney General formed a task force to investigate pharma-doctor interaction. And now, perpetual pharma bloodhound Sen. Charles Grassley (R-IA) is sniffing around the cases.

You'll recall that two former Amgen reps are suing the company, alleging that they were forced to participate in improper and illegal marketing activities to promote Enbrel. According to the suits, the reps were told to persuade docs to prescribe Enbrel for off label uses, including to patients who wouldn't benefit. One of the reps says he was told to rummage through private patient files as part of a plan to persuade insurers to cover the drug.

Well, the Senate Finance Committee wants to hear more: One of its investigators asked for a conference with the lawyer representing the ex-reps. It's part of Grassley's ongoing probe of drug-marketing practices. Undoubtedly we'll hear more from the committee soon.

- read this item from Pharmalot

Related Articles:
Amgen reps allege marketing abuse. Report
Drug marketing costs double R&D. Report
Too much off-label regulation? Report
Alzheimer's: A new indication for Enbrel? Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.